The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Letter to the EditorFull Access

Olanzapine-Induced Somnambulism

To the Editor: Somnambulism has been reported with the use of classical antipsychotics (1). However, to our knowledge, there have been no reports of somnambulism associated with the use of atypical antipsychotics. We present two cases of somnambulism induced by olanzapine in patients with no previous history of somnambulism despite several years of antipsychotic pharmacotherapy.

Mr. A was a 63-year-old man with a 41-year history of schizophrenia who was seen as an outpatient in a specialized clinic for schizophrenia. He had taken risperidone for several years but was switched to olanzapine, which was increased over 10 months to 20 mg at bedtime. After 1 week at this dose, he complained of sleepwalking most nights, during which no injuries occurred. The sleepwalking was witnessed by a roommate. Mr. A’s olanzapine dose was gradually decreased over 6 months, and he began taking risperidone. Even when he was taking only 5 mg of olanzapine, his sleepwalking persisted, but it ceased immediately when he stopped taking it. He reported no personal or family history of epilepsy, somnambulism, or other parasomnias. A computerized tomography scan of his head and EEG were normal. His other medications included valproate, 1750 mg/day, and procyclidine, 15 mg/day.

Ms. B was a 62-year-old woman with a 35-year history of schizophrenia who was being treated with loxapine. She started taking olanzapine and reached a maximum dose of 20 mg at bedtime. She then reported sleepwalking for 6 months. Valproate was added to her medication regimen, but her somnambulism persisted. She was switched from olanzapine to risperidone over 3 months; the somnambulism decreased in frequency with tapering doses and ceased after discontinuation of olanzapine.

Somnambulism arises during slow-wave sleep (stages 3 and 4) (1) and reflects impairment in the normal mechanisms of arousal from sleep, resulting in partial arousals during which motor behaviors are activated without full consciousness. Drug-induced somnambulism may represent a physiological state during slow-wave sleep that mimics primary somnambulism (1). Periodic leg movements of sleep may trigger sleepwalking by increasing arousal. Periodic leg movements of sleep and restless legs syndrome have been reported in conjunction with olanzapine therapy (2).

Two recent studies (3, 4) have demonstrated that olanzapine significantly increases slow-wave sleep. This is likely mediated by serotonin 5-HT2C receptor blockade because ritanserin, a 5-HT2C antagonist, increases slow-wave sleep (5). In contrast, clozapine decreases slow-wave sleep in patients with schizophrenia who were previously antipsychotic free (6).

References

1. Charney DS, Kales A, Soldatos CR, Nelson JC: Somnambulistic-like episodes secondary to combined lithium-neuroleptic treatment. Br J Psychiatry 1979; 135:418-424Crossref, MedlineGoogle Scholar

2. Kraus T, Schuld A, Pollmacher T: Periodic leg movements in sleep and restless legs syndrome probably caused by olanzapine (letter). J Clin Psychopharmacol 1999; 19:478-479Crossref, MedlineGoogle Scholar

3. Salin-Pascual RJ, Herrera-Estrella M, Galicia-Polo L, Laurrabaquio MR: Olanzapine acute administration in schizophrenic patients increases delta sleep and sleep efficiency. Biol Psychiatry 1999; 46:141-143Crossref, MedlineGoogle Scholar

4. Sharpley AL, Vassallo CM, Cowen PJ: Olanzapine increases slow-wave sleep: evidence for blockade of central 5-HT2C receptors in vivo. Biol Psychiatry 2000; 47:468-470Crossref, MedlineGoogle Scholar

5. Idzikowski C, Mills FJ, Glennard R:5-Hydroxytryptamine-2 antagonist increases human slow wave sleep. Brain Res 1986; 378:164-168Google Scholar

6. Hinze-Selch D, Mullington J, Orth A, Lauer CJ, Pollmacher T: Effects of clozapine on sleep: a longitudinal study. Biol Psychiatry 1997; 42:260-266Crossref, MedlineGoogle Scholar